Journal article
Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: An ANZGOG substudy of the PORTEC-3 intergroup randomised trial
P Blinman, L Mileshkin, P Khaw, G Goss, C Johnson, A Capp, S Brooks, G Wain, I Kolodziej, AS Veillard, R O'Connell, CL Creutzberg, MR Stockler
British Journal of Cancer | SPRINGERNATURE | Published : 2016
DOI: 10.1038/bjc.2016.323
Abstract
Background:To determine the minimum survival benefits that patients, and their clinicians, judged sufficient to make adjuvant chemotherapy (ACT) worthwhile, in addition to pelvic radiotherapy, for women with high risk and advanced stage endometrial cancer.Methods:Eighty-three participants in the PORTEC-3 trial completed a time trade-off questionnaire before and after adjuvant therapy; 44 of their clinicians completed it once only. The questionnaire used four hypothetical scenarios including baseline survival times without ACT of 5 and 8 years, and baseline survival rates at 5 years without ACT of 50 and 65%.Results:Over 50% of patients judged an extra 1 year of survival time or an extra 5% i..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work was supported by NHMRC Project Grant 2009-2011 #570894 and Cancer Australia Priority-driven Collaborative Cancer Research Scheme 2012-2015.